Mediwatch is a small company destined to become a much bigger fish by the time this year is out. Mediwatch are already a market leader in urological medical diagnostics equipement and are currently exporting their products throughout the UK, Canada, Europe, India and Japan. That doesn't leave much of the globe left for them to capture - until you remember the good ol' US and China. These are the two massive markets which are destined to be added to MDW's export client portfolio by the end of 2005.

Website: www.mediwatch.com

The company is currently heavily undervalued. This is probably because Mediwatch's speciality is not a very glamourous business to be in as their equipment is used extensively to diagnose prostate cancer in men and other nasty urological conditions affecting both men and women. However, don't let that put you off investing in these guys. This is big business and is growing at an exponential rate as more and more people globally become health-aware as they get older. Mediwatch normally supply their products through to global markets via distribution agreements. They already have the best of distribution partners in the well known US medical distributor CR Bard who supply Canada and Europe and GE Medical who supply Japan. The UK business is handled by Mediwatch's own dedicated sales team. US FDA approval was gained for MDW's products at the start of last year, however a whole year of US legal wrangling meant that they were unable to seek a suitable partner for the crucial distribution agreement until the start of this year. This distribution agreement is expected by the board to have a "significant effect" on the share price so they are reluctant to give any clues as to when it will be signed, sealed and delivered. The general consensus is that this US distribution agreement will be announced in July/August. In China and Hong Kong, MDW have done things the other way round. They have set up distribution agreements with major Asian medical equipment distributors and have stock already out there waiting to sell into the markets - all they are waiting for is SDA approval (which is a "rubber stamp") from the Chinese authorities - this can take anything up to 12 months to come through and MDW applied during Autumn 2004 - so even more good news coming soon this year. Epidemiological data from British Association of Urology conference last year: On average 30-45% of all men between the age of 50 and 70 have at least one PSA test per year in the US / Italy / Australia. If that's not enough to convince you to invest a few hard earned coppers in MDW, they are also developing a PSA stick test product (PSAWatch) which is revolutionary and causing some excitement in medical circles. This product can also be adapted (at very low cost) for a whole spectrum of medical disciplines from Cardiology to Veterinary Practice! This product is likely to be released in the next few weeks. Philip Stimpson the CEO has said that this product is going to be their "gold mine" - I'm sure it will prove to be ours too.

The NHS are trying to save money (obviously) left right and centre.

The London Urology Centre is a new website.

The new Elemental website is targeted for the UK market for both NHS and the Private Practice.

They are both heavily linked to Mediwatch.

Mediwatch has the cream of Medtronic's Urology suit.

Mediwatch have their own equipment that compliments the newly acquired Medtronic equipment to form a complete package for any Practice to set up a reasonably cheap Urology department to carry out accurate tests once only available to expensive systems found in Hospitals and now with the technology to send data directly to a major Hospital for further analysis or record keeping.


Well,I have dug me hole now-lol


From small General Practices which may only require the basic systems to relay the information to a city centre Private Practice which would have the full range of MDW products which in turn would either carry out further investigations or pass on to a NHS Hospital with a leaner workforce (due to preliminary tests being carried out at the GP level)to further the tests or combine with the Private Practices to increase patient through put............

Just some thoughts after looking at the way a small UK company has acquired a major USA/World companies Urology department ie Medtronic and with the strong links both companies have had with the NHS and with cost cutting excercises which are made achievable as modern,accurate and cheaper products come to the market place!
Along with two recent companies wanting to be involved with MDW and are.


Hope this doesn't sound like a ramp as it's not meant to be and if floored the day crew will soon put me right-lol

Good Evening and what a splendiferous,if not pretty,win by the Boro tonight!

Just typing outloud here relating to a Department of Health working group report from 13th JANUARY 2004 (I have looked at it quite often since it's arrival on the web,many months ago) and with Newsnight tonight and the ever changing NHS(only a very small part in deciding to write this tonight)

First of all our CEO Philip Stimpson,although not present at the particular meeting I am quoting from but non the less was heavily involved in these meetings over the time.

So,I will be quoting what I think are key points from the minutes which I believe were part of MDW's plan with or without assistance :

AGENDA ITEM 3: MATTERS ARISING

3. Progress reports on the last meetings "action points" were taken:

PRIORITIES
Bob Bish circulated statistical information on UK healthcare device exports to the EU, certain Accession States, the USA, China, India and Japan (Annex1).

HUB AND SPOKE HEALTHCARE NETWORKS
At the first meeting the Group noted the "hub and spoke activities" of American Healthcare Groups in overseas markets. They wondered whether the NHS could become a competitor. Stuart Smalley stated that he believed that the NHS would not develop satellite facilities overseas in the foreseeable future.


RESOURCES FROM OFFICIAL SOURCES
Bob Bish reported that UKT&I spend on supporting healthcare exporters amounted to 1.2m. The largest element was 644k for support for exhibitions and seminars overseas. The total figure did not included departmental running costs such as pay. David Crossman expressed concern that these figures did not represent an accurate total spend. Bob Bish acknowledged that the figures were central figures and did not include RDA/regional and other government expenditure on trade.

AGENDA ITEM 4: OVER ARCHING ASSUMPTIONS

4. Following a short discussion it was agreed that it was essential to have an agreed base of assumptions from which a work programme could flow. A draft of over arching assumptions was tabled (Annex3) and comments invited. The draft was approved and Assumption 4 "global success is contingent upon success in the USA" strongly endorsed by Arthur Kay and David Crossman. In their view even inexperienced exporters could not afford to ignore 50% of world demand for healthcare products. Market dynamics would quickly indicate whether a product was competitive; something that happened more slowly in other territories. Moreover FDA approval was a key selling point outside the USA.
******I put the stars in for the above line and "global success is contingent upon success in the USA" strongly endorsed by Arthur Kay and David Crossman******


It was considered that UKTI support for companies exporting or wishing to export to the USA should be based upon support to attend appropriate major US conferences / exhibitions. Attendance at general purpose medical exhibitions in the USA is considered of marginal benefit. This support should be based on individual company specific needs.

****Me again,the above shows the path MDW followed/follows and along with combining with a major USA company at such events ie Medtronic and with MDW then taking over their Urology section (all with FDA approvals which ties in with the 'stars' above this one....***********************8

. Discussion focused on Assumption 5 "China likely to become the leading market in the world" and this was endorsed. The meeting were advised of the joint work between UKTI and DHI and the real market opportunities which had been identified in Shanghai. It was agreed that WG4 should recommend that both China and the USA be regarded as key markets and programmes to exploit the potential developed accordingly.
******Only me,well we have the USA tied up and already have outlets to China which I'm sure will be improved somewhat with our new hold on this sector******



HITF WG 4 Suggested Work Themes
***There are a few sections to this but rather than listing them they will be covered in my conclusion(the link to the whole document is at bottom of page)*********

AGENDA ITEM 6: ANY OTHER BUSINESS

TEAMS OF EXPERTISE

7. Peter Simpson (not to be confused with Stimpson,as I often do) strongly recommended the creation of multi disciplinary teams containing different levels of expertise. The teams would focus on one aspect of healthcare PFI, diabetes and so on. The expertise could then be drawn down on a properly managed basis rather than on an ad hoc basis that typified current activity. It would also ensure that the appropriate level of expertise was deployed on each occasion.


Conclusion:

1. Both MDW and MDT have been key players in our NHS

2. The points put forward have been those that have been achieved by Mediwatch (MDW),starting from about the time of this meeting took place!

3. MDW have setup an existing supplier to the NHS ie Elemental Healthcare Ltd to distribute their products/systems to the UK market,that is both the Private sector and the NHS
http://www.elemental-healthcare.co.uk/

4. "Stuart Smalley stated that he believed that the NHS would not develop satellite facilities overseas in the foreseeable future."

Well,MDW went one better and produced a satellite facility which by all accounts is up and running in Florida USA,which could become the main 'Hub' for the world.

My point is that the NHS formed a group in early 2000 to find a profit margin abroad but from the way I see it,as in most massive companies they were too slow.MDW saw the market and with a base product in Urology ie PSAwatch started on the long road (as far as share holders were concerned)in building up a 'one stop Urology Shop' where all their systems talk to each other via normal networking or the latest Bluetooth.This enables all the various Urology tests to be sent to a central data base ie From the GP to a central function ie Hospital.


The above is just my view from the doc.link below that has plagued on me mind for a few years-lol.

I am not saying buy these shares but any opinion on the above would be most welcome.


http://www.advisorybodies.doh.gov.uk/hitf/wg4meeting2.htm

The AGM is tomoorrow and unfortunately I won't be able to go. I have already spoken to Kevin Middas and they seem to be well on top of everything (even if we have thought they aren't).The product is to be launched at the end of March at the EAU. This is the biggest urology meeting outside the USA... attended by 12,000 urologists.
I also spoke to the PR company.. and am impressed, so that bodes well for the future presentations needed.
The importance of getting the PSA watch into the markets to detect this ferral disease is only too important and for those who don't read teh competitors MDW board, this post by Reg sums it up (reproduced with his permission)




BoringREG - 26 Feb'07 - 11:55 - 9 of 13


Most blokes


Prostate problems. Equally, most think that Prostate problems are what old blokes get.

Back in the summer of 2004 I certainly had these opinions. In fact, when I went to my GP with what was proving to be a problem my GP - a bloke of around my age - needed to be persuaded to send off a blood sample. In fact he suggested I was too young to worry about Prostate cancer and doubted that a PSA test was needed.

I was 53.

Within a couple of weeks I received a letter from my GP telling me that my PSA levels were higher than normal and I would need to go to a urologist to have an internal examination which would also include a biopsy.

My PSA level was 19 - normal would have been below 4.

Unfortunately the examination proved positive and a further PSA test showed it had risen to 24. Also, unfortunately, the cancer had broken out of the gland and, therefore, surgery was not an option.

Had I gone for a screening before I did - persuading my GP to do it and send it off - the options would have been increased.

As it is, the cancer is inoperable and I need to have medication to control its growth.

One of the associated problems of Prostate cancer is that it usually spreads to your bones. This has happened to me as well so, as well as regular MRI/CT scans I have also had 3 bone scans to assess the level of development of prostate cancer on my bones.

I am now 55 and the cancer is being "managed" using hormone treatments which, unfortunately, have a limited impact and, eventually, the cancer will become hormone resistant.

My oncologist has changed the medication a few times and, although the initial treatment proved to have an immediate effect that is no longer the case. Equally, the alternative initially had an impact but that too is no longer having the same impact.

How do they measure how I'm getting on, what interventions to take - regular blood tests to check my PSA level.

Going to the Cancer centre a week before seeing the consultant means that I always have that dreaded wait until I know whether the drugs are doing OK or not.

All in all, for me and thousands of other blokes in their middle and older ages, the arrival of the PSAWatch and MDW's other products are critical:

a) More frequent, simple, screening which would lead to early intervention
b) Simple monitoring for those unfortunate enough to present too late
c) Simple monitoring for those who have surgical/radiotherapy treatment.

I have a lot of money invested in MDW for both personal and financial reasons.

PSAWatch will revolutionise the way Prostate (and other cancers) can be detected through mass screening at a Primary and Acute Points of Care. The "market" is huge and, being one of the potential beneficiaries I believe it will be massive.

There are plenty of blokes out there whose lives - and life expectancy will be transformed by this company's innovative products.

It's just that they don't want to see it or think about it - YET.

Hopefully, this little tale will inspire blokes out there to go and get tested. Very soon it will be a very simple task - because of PSAWatch.

The other thing you all need to do is make sure your GP is prepared to test you. Mine has been persuaded to do it more frequently and has, because of my experience now actually tested himself. Many practices, he assures me, are reluctant to test - because of their belief that it can lead to positive negatives i.e. false alarms.

Which is better, one wonders, a short period of uncertainty and the relief that comes from a false alarm or leaving the problem until it is too late for effective surgical intervention. I know what I would have preferred - although it would have put me in the hands/knives of the Willydoctors. If only !!

I'm not that worried whether it also inspires you to invest in the company. I know it will be a massive success. Whether I get to benefit financially may be another issue - but my wife and kids will :)

Boring Old REG

Let's hope that this is out there in the surgeries quicker rather than later , ... I have a feeling it will.
Jules

Cheerful statement from the AGM:

Mediwatch PLC
01 March 2007





Issued by Citigate Dewe Rogerson Limited, Birmingham
Date: Thursday 1st March 2007
Immediate Release

Mediwatch plc
('Mediwatch' or 'the Company')

AGM Statement

At the Annual General Meeting of Mediwatch Plc, held at 10.00 am today, Chairman
Dr John Forrest told shareholders:

'I am pleased to report that the current year has started well and that sales
are running ahead of expectations. The transition arrangements with Medtronic
A/S have worked very well with an on-going orderly take over of this urological
diagnostics business, whilst our new sales office in the USA is also generating
new business.

'On 21 February 2007, we announced that we had received CE approval for our
quantative point-of-care diagnostic test for prostate disease, the PSAwatchTM.
The Company intends to launch PSAwatchTM and the Bioscan reader system at the
forthcoming European Association of Urologists ('EAU') Meeting in Berlin on 21
-24 March 2007 with sales of the PSAwatchTM system into the European market
expected to commence in the second calendar quarter of 2007. The US FDA approval
is being targeted for Summer 2007 and, subject to the same, the Directors
anticipate that marketing in the US will commence in the Autumn 2007.

'On a personal note, the demands of my personal business activities outside
Mediwatch now require that I spend more time abroad. I have decided therefore to
stand down as Chairman and retire from the Board of Mediwatch on 1 April 2007.
My successor will be Omer Karim, who is currently a Non-Executive Director with
the Company. Omer, a Consultant Urologist, has been involved with the Company
since its inception in the late 1990's and I am confident that he will lead the
Company through its next exciting phase of growth.

'As we indicated in our Annual Report & Accounts, we are progressing the recruitment
of a full time Finance Director and the Board anticipate making an appointment in
the near future.'

All Resolutions were duly passed.

Enquires:
Mediwatch plc Citigate Dewe Rogerson
Philip Stimpson, Chief Executive Fiona Tooley, Director
Kevin Middis, Finance Director Katie Dale, Senior Account Manager
Tel: +44 (0) 1788 547888 Tel: +44 (0) 121 455 8370

Looks good to me.


'I am pleased to report that the current year has started well and that sales
are running ahead of expectations. The transition arrangements with Medtronic
A/S have worked very well with an on-going orderly take over of this urological
diagnostics business, whilst our new sales office in the USA is also generating
new business.

That is a good , honest statement and I am pleased that Omer will become chairman. He is passionate about MDW and a damn good urologist to boot:-)

Nice 100k to round off a very good day in both news and SP.

Mediwatch will grow and grow this year,that's all there is to it! (in my humbly opinion of course)

I've researched the company for so long now-lol

You have, banjo. Full marks to you :)
Still got to break 11 pee though, in my humbly thingie.
Hope it was a good omen today, staying blue and all that ;)

Evening chocolat,
Sorry for me simplistic statement-lol

Yes,agree the 11/12p barrier requires a good passing through which I believe it will do and move on pretty quickly from there as revenue/publicity increases.The problem has been as in a lot of AIM companies,in setting out time scales and not achieving them.
MDW have been about two years late with PSAwatch but in the mean time have managed,over the last year and a half or so,to negotiate the Medtronic deal and open the Florida USA section along with an increase in orders with Bard and bring in new distribution deals from other companies,now that they have increased their distribution network.

I'm always prepared for falls in SP short term (especially after I say anything on a BB-lol) but overall MDW have took their time and done things right to form a stable global company that will reward both themselves and the long term holders ie me!

I think the chart below tells a story in that the 200 has leveled out over the last two months which appears to coincide with the increased news flow...positive-imo

This from the Prostate Cancer Charity site,

I know that some will already have seen this as it is included in a different thread. I am after as many signatures as I can generate so have started up a new topic just for this. Thanks to those who have already signed by the way.

If any one wants to sign the petition re testing it has been accepted on the Downing Street website and can be found at

http://petitions.pm.gov.uk/psa-testing/

It reads as follows


We the undersigned petition the Prime Minister to begin regular
testing for prostate cancer in men between the ages of 40 and
70

Prostate cancer is the largest cause of male deaths. A blood
test, known as PSA, can indicate that there is a problem that
needs investigating. In the Tryol district of Austria this is
being done and the mortality rates have fallen. Too many men
are being diagnosed only when it is too late for treatment to
be more than palliative.

Elemental force
FORMER COMPETITORS Adam Power (of Mantis Surgical) and David Marsh (of Gyrus/ACMI) have joined forces to create a new medical device distribution company, Elemental Healthcare Ltd. Based in Hungerford, Elemental has full direct coverage of the UK. It sells innovative products in diagnostic urology and minimally invasive surgery. For more information, visit www.elementalhealthcare.co.uk.

http://www.ontargetmag.com/article.aspx?issueID=86&articleID=529

"It is almost a year since the 250-page White Paper Our health, our care, our say was published, and I wonder if all the readers of On Target have looked inside its covers. If you havent, you really should because in 2007, dramatic changes will begin as services start being divested from the hospital sector to primary and community care settings. This will have major knock-on effects for diagnostic, medical device and medical equipment companies. This article looks at some of the main changes and their implications."

http://www.ontargetmag.com/article.aspx?issueID=86&articleID=527

Looks like we are in the right position at the right time regarding the UK anyway.I would have thought this would be a world wide initiative. :-)

(From the link in post above)

"The White Paper covers a whole battery of issues, but a key aspect is that six clinical areas are to be targeted for the shifting of services into primary care: orthopaedics and trauma, dermatology, gynaecology, urology, ENT and general surgery. The aim is to move some 5% of total hospital services out into primary and community care settings over a 10-year period."

Just been looking around and the 'Point of Care/Near Patient Testing' is becoming huge!

I have obviously known about this new direction that world health services are entering but I hadn't realised the speed that countries are taking it up.

I've had a lapse in my own research of some 6 months but started again a few months ago.....I've missed a lot!


The fact that countries in these modern times are having to cut dramatically the waiting times on all aspects of patient care is as I see it,the major key here.The current infrastructures cannot cope with any more through put to meet these new directives due to the extra cost and the hospitals being too small to cope with the ever increasing population.

Regarding MDW and the role they will play in 'Point of Care/Near Patient Testing'is as follows:

1. MDW have a complete Urology suit that can be used in a small practice situation at a fraction of the cost that a similar system in a major hospital would have cost say 10 years ago.This is all due to new systems being now both accurate and cheap due to changes in technology.

2. MDW systems are bluetoothed to enable results to be correlated to a central database which could then be sent to the local major hospital when patients require a more in-depth examination.The major hospitals will now have more time to look into a patients problems as the main preliminary testing has already been done via MDW's products at a local level!

3. MDW have their USA based sales & marketing operation up and running this month,which was all part of the Medtronic agreement that took so long to sign and imo effected the SP during this time (about 18 months) but I see why now and worth the wait!

4. We already distribute throughout the EU,China and Hong Kong but I invisage a much harder drive into these markets this year,now that we have a complete Urology system to offer.

5. This was a big bonus:

"International Distribution Agreement with T-DOC

On 22 January, 2007, we announced that we had entered into a distribution
agreement with US based T-DOC. Under the agreement which covers USA, Canada and
the EU, Mediwatch will be distributing the T-DOC range of disposable,
pressure-sensing, air charged catheters. These pressure sensing catheters are
key to performing diagnostic procedures with the new range of urodynamic
equipment recently from Medtronic Inc. and this relationship is a significant
step forward for our new urodynamics business.

Considerable, recurring sales of these disposable catheters in excess of US$3.0
million per annum have already been established by Medtronic over the last three years.Looking ahead, we believe that the distribution of disposable catheters will provide Mediwatch with a recurring income stream from within an established market,whilst also strengthening our urodynamics business."

6. and from the Results:

Outlook

Awareness of urological disorders and patient-specific disease management is
increasing with on-going advances in the quality and specificity of diagnostic
testing. Mediwatch is striving to develop and market faster, simpler, and less
invasive diagnostic products to save lives and restore quality of life for
people with urological conditions.

The Directors consider there is considerable optimism for 2007 and beyond and,
as we stated in our December trading update, the new financial year (ending 31
October 2007) has started in-line with management expectations and budgets.

The challenge now is to ensure that we have the resource and capability to match the anticipated demand for the enlarged product range and to this end, we have reviewed resources and made the necessary changes to support our growth.

We have already commenced establishing independent relationships with
Medtronic's worldwide distribution network and as part of this process we
co-hosted an international dealer conference to introduce the established
Medtronic distributors to the new and extended range of Mediwatch equipment. I
am pleased to report that we have had very positive feedback to date.

The Directors expect that there will continue to be an improving trading
performance in the current year following the acquisition of the Medtronic
Urodynamics business, the establishment of the US sales, service and marketing
operation coupled with the on-going development programme and marketing of new
products.

Overall, the Group is in an excellent position to exploit and benefit from the
opportunities it has already identified and we will keep shareholders updated of our progress as appropriate.

7. PSAwatch although still very important to MDW is not the only banja string in the pack,as can be seen from the above!What it is though is a one of a kind very accurate test for PSA levels (with other tests nearly complete or in various stages of completion)which can be combined with a whole suit of other MDW Urology products for cross referencing purposes and data gathering..... A 10 minute wait time from test to result instead of a week or more at a fraction of the cost!

I have finished now-lol

Have we got the 'Point of Care/Near Patient Testing' Urology world market sewn up?

I think we have!


http://www.elemental-healthcare.co.uk/portascan.html

http://www.elemental-healthcare.co.uk/portaflow.html

http://www.elemental-healthcare.co.uk/multiscan.html

http://www.elemental-healthcare.co.uk/images/G3.pdf

http://www.elemental-healthcare.co.uk/images/U.pdf

http://www.elemental-healthcare.co.uk/images/G2.pdf

and PSAwatch when it's updated like the above.

I think we have to give them a bit of time (pretend you have just bought in and not grown a 6' beard while waiting).

If we take the EU as this is the area we have a complete suit now,with CE approval for PSAwatch now granted.

We have Elemental Healthcare Ltd distributing all our products in the UK:

"With the increasing pressure on the NHS to move diagnostic services away from the acute settings, PCTs are having look for innovative solutions to fulfil these services at the point of care.

Diagnostic urology and uro-gynaecology have been identified by the NHS as a priority service to move to the point of care setting. Until now the level and complexity of the diagnostic tools has been expensive in both cost and skill base requirements.

Today, Elemental Healthcare Ltd, can now offer the UKs most effective one stop solution for diagnostic urology through the Mediwatch urological assessment system.

Key to the system is the Multiscan which offers real time imaging of the bladder, kidney and prostate. Portable, easy to use the Multiscan will manage data from all the other components of the system via blue tooth technology thereby enabling complete assessment reports at your figure tips.

PSAwatch provides a fast effective solution for the management of of new & recurrent prostate disease with accuracy of 98% (Check Figure). Ease of use combined with state of the art assessment analysis allows the user clear result with 10 minutes. Linked to the Multiscan by blue tooth the PSA result an be used with the the measured prostate volume to calculate the PSA density.

Uroflow Systems offers an integrated solution for the assessment of urinary flow and is easily adapted for both male and female patients. The assessment result can be reviewed separately or as a combined assessment report via the Multiscan system."

http://www.elemental-healthcare.co.uk/clinical_solutions_diagnos.html

There was also these articles:

http://urologycentrelondon.co.uk/news_prostateseminar.html

http://urologycentrelondon.co.uk/news_psadevelopments.html

http://www.ontargetmag.com/article.aspx?issueID=86&articleID=529

We also have the new German distributors (Promedia) who I'm sure will supply the whole MDW range as per Elemental and I would expect further distribution deals to be announced throughout this year,in Europe.

I'm sure,as has been stated by MDW that the Florida USA branch is doing better than expected and this will continue to improve as the year pans out and PSAwatch nears FDA approval.

I can't fault what they have achieved so far and we also have this to look forward to:

"The Company intends to launch PSAwatchTM and the Bioscan reader system at the
forthcoming European Association of Urologists ('EAU') Meeting in Berlin on 21
-24 March 2007 with sales of the PSAwatchTM system into the European market
expected to commence in the second calendar quarter of 2007."

and a bit later:

AUA - May 19-24 Anaheim - Stand 2816
This will be the first AUA where Mediwatch USA has exhibited independently -
an opportunity all our sales managers are eagerly looking forward to.

There is also the Medilink Network which Mediwatch belong to,I have sent them an email asking them to update the Mediwatch page as it's a bit out of date.
Overall though they make a good platform for Mediwatch to use.

http://www.medilink.co.uk/national.html

This might bring a bit of revenue in:


"45 Million Boost for West Midialnds Health Trusts

Midlands Health trusts will recieve a 45 million booast for next year, 22 million being handed over to primary care trusts.

This is all part of the plan to bring facilities closer to the patient and to cut patient witing times; this will mean the purchase of new equipment and acquiring new buildings. The local NHS will distribute this money according to local needs, and will see local hospitals recieveing around 10.5 million extra next year."



Source: Birmingham Post (08-02-2007)


http://www.medilinkwm.co.uk/news/display.php?id=284



The above is a very good example of the direction medical testing as in 'Point of Care/Near Patient Testing'is heading and not just in the UK but world wide!

This was observed and remarked upon over on the dark side:

When you type this link in:

http://www.medtronicurodynamics.com/

Which is a great piece of publicity as the link is posted on various medical sites to find out further information on what was once their products but now MDW's

It has been commented on,that the MDW web site requires updating and after I emailed the company they replied with along the lines of 'they are in the process of redeveloping all of their PR functions including the web site.'

All looks good to me.....